Edition:
United Kingdom

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

12.70CNY
13 Dec 2018
Change (% chg)

¥-0.46 (-3.50%)
Prev Close
¥13.16
Open
¥12.97
Day's High
¥12.97
Day's Low
¥12.40
Volume
29,120,438
Avg. Vol
17,023,145
52-wk High
¥32.83
52-wk Low
¥10.62

Select another date:

Fri, Nov 9 2018

BRIEF-Zhejiang Huahai Pharmaceutical Clarifies Reports Related To Sandoz's Product Recall

* SAYS IT CLARIFIES ONLINE REPORTS ON HUAHAI BEING INVOLVED IN MANUFACTURING RAW MATERIALS CONTAINING NDEA IMPURITIES THAT PROMPTED SANDOZ TO RECALL A BATCH OF ITS LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE TABLETS

EU places China's Zhejiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

UPDATE 1-EU places China's Zhejiang Huahai under increased supervision

Oct 15 European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

EU places China's Zheijiang Huahai under increased supervision

Oct 15 European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, after an inspection revealed lapses in quality management at the drugmaker's factory in China.

Embattled Chinese drug maker to get $43 mln in government support

SHANGHAI, Oct 14 A Chinese city government has given 300 million yuan ($43 million) to drug maker Zhejiang Huahai Pharmaceuticals, the company said, after it was recently faulted by U.S. and European regulators over production issues at one of its plants.

CORRECTED-(OFFICIAL)-UPDATE 3-FDA halts imports from China's Huahai Chuannan plant

SHANGHAI/NEW YORK, Sept 28 The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced at China's Zhejiang Huahai Pharmaceuticals Chuannan factory, after a recall of one of its drugs that contained a probable carcinogen.

Chinese drugmaker Huahai tumbles after FDA shutout

SHANGHAI Shares of China's Zhejiang Huahai Pharmaceuticals Co Ltd tumbled in early trade on Monday, the first day of trading since the U.S. Food and Drug Administration halted imports of drug ingredients or medicines made by the company.

Global health regulators find second toxin in common heart drug

(This version of the September 14th story changes final paragraph to show representative did not immediately respond to a request for comment)

Global health regulators find second toxin in common heart drug

(This story has been refiled to change final paragraph to show representative did not immediately respond to a request for comment.)

Toxin at heart of drug recall shows holes in medical safety net

SHANGHAI/LONDON A toxin inadvertently produced in the manufacture of a widely prescribed medicine but not spotted for years raises questions about regulators' ability to detect risks in a sprawling global drug supply chain increasingly reliant on factories in China.

Select another date: